The ALPMY chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ALPMY chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ALPMY stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
View ALPMY Detailed Price Forecast - CNN Money | View ALPMY Detailed Summary - Google Finance | ||
View ALPMY Detailed Summary - Yahoo! Finance | View ALPMY Stock Research & Analysis - Zacks.com |
View ALPMY Trends & Analysis - Trade-Ideas | View ALPMY Major Holders - Barrons | ||
View ALPMY Call Transcripts - NASDAQ | View ALPMY Breaking News & Analysis - Seeking Alpha | ||
View ALPMY Annual Report - CompanySpotlight.com | View ALPMY OTC Short Report - OTCShortReport.com | ||
View ALPMY Fundamentals - TradeKing | View ALPMY SEC Filings - Bar Chart | ||
View Historical Prices for ALPMY - The WSJ | View Performance/Total Return for ALPMY - Morningstar | ||
View the Analyst Estimates for ALPMY - MarketWatch | View the Earnings History for ALPMY - CNBC | ||
View the ALPMY Earnings - StockMarketWatch | View ALPMY Buy or Sell Recommendations - MacroAxis | ||
View the ALPMY Bullish Patterns - American Bulls | View ALPMY Short Pain Metrics - ShortPainBot.com |
View ALPMY Stock Mentions - StockTwits | View ALPMY Stock Mentions - PennyStockTweets | ||
View ALPMY Stock Mentions - Twitter | View ALPMY Investment Forum News - Investor Hub | ||
View ALPMY Stock Mentions - Yahoo! Message Board | View ALPMY Stock Mentions - Seeking Alpha |
View Insider Transactions for ALPMY - SECform4.com | View Insider Transactions for ALPMY - Insider Cow | ||
View ALPMY Major Holdings Summary - CNBC | View Insider Disclosure for ALPMY - OTC Markets | ||
View Insider Transactions for ALPMY - Yahoo! Finance | View Institutional Holdings for ALPMY - NASDAQ |
View ALPMY Stock Insight & Charts - FinViz.com | View ALPMY Investment Charts - StockCharts.com | ||
View ALPMY Stock Overview & Charts - BarChart | View ALPMY User Generated Charts - Trading View |
U.S. Stocks Erase Early Gains
Posted on Monday April 15, 2024
U.S. stocks extended recent declines as March retail sales increased more than expected, causing traders scale back bets on Fed rate cuts.
China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for enfortumab vedotin with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Posted on Thursday March 28, 2024
Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, "Astellas") today announced that on March 27, 2024 the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted the supplemental Biologics License Application (sBLA) for enfortumab vedotin with KEYTRUDA® (pembrolizumab) as a combination therapy for the first-line treatment of adult patients with previously untreated locally advanced or metastatic urothelial cancer (la/mUC). If appr
Astellas Receives Permanent J-code for IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy
Posted on Tuesday March 26, 2024
Iveric Bio, An Astellas Company (TSE: 4503, President and CEO: Naoki Okamura, "Astellas"), today announced the U.S. Centers for Medicare and Medicaid Services (CMS) has assigned a unique, permanent Healthcare Common Procedure Coding System (HCPS) J-code for IZERVAY™ (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The new J-code, J2782, is effective April 1, 2024.
Astellas' VYLOY™ (zolbetuximab) Approved in Japan for Treatment of Gastric Cancer
Posted on Tuesday March 26, 2024
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that on March 26, 2024, Japan's Ministry of Health, Labour and Welfare (MHLW) approved VYLOY™ (zolbetuximab), an anti-claudin 18.2 (CLDN18.2) monoclonal antibody for patients with CLDN18.2 positive, unresectable, advanced or recurrent gastric cancer. VYLOY is the first and only CLDN18.2-targeted therapy approved by any regulatory agency in the world.